Is the amyloid-beta hypothesis still considered the leading theory for Alzheimer's?

According to Dr. Gonzalez-Lima, the amyloid-beta hypothesis, which suggests that amyloid deposition causes Alzheimer's, is largely false for late-onset dementia. There's no correlation between amyloid-beta deposition and cognitive decline in older individuals, and many cognitively normal brains can show similar amyloid pathology post-mortem.

What is the vascular hypothesis of Alzheimer's disease?

The vascular hypothesis proposes that late-onset Alzheimer's is centrally a progressive neuronal energy crisis caused by chronic hypoperfusion (impaired blood flow) to the brain and impaired mitochondrial respiration. This chronic reduction in blood supply, regardless of the cause, leads to functional deficits and eventually atrophy.

How does aging affect cerebral blood flow and brain energy?

Between the ages of 22 and 60, there is a natural decrease of about 20% in blood supply to the brain, roughly half a percentage point per year. This chronic hypoperfusion is compounded by arterial stiffness, irregular vessel walls creating turbulence, and mechanical pressure on capillaries from the body's attempt to auto-regulate blood pressure, all leading to reduced tissue oxygenation.

What is the role of cytochrome oxidase in Alzheimer's disease?

Cytochrome oxidase (Complex IV) is the rate-limiting enzyme in the electron transport chain, crucial for converting oxygen to water and producing chemical energy (ATP). In Alzheimer's brains, this enzyme is found to be inhibited and not in its catalytic functional state, leading to a severe energy deficit even before structural damage is evident.

How can methylene blue benefit brain health and Alzheimer's prevention?

Methylene blue acts as an electron donor and cycler within the mitochondrial electron transport chain, providing an alternate route for respiration and accelerating energy production. At low, non-toxic concentrations, it can bypass inhibited complexes and is neuroprotective against metabolic insults, making it a promising 'metabolic pharmacology' intervention.

Are there other historical uses for methylene blue?

Yes, methylene blue has a rich history as medicine; it was the first synthetic chemical used for medicinal applications. Paul Ehrlich discovered its ability to stain nervous tissue and its effectiveness against the malaria parasite, Plasmodium falciparum, for which it was the primary treatment for decades. It was also used for urinary bladder infections and to treat blood for transfusions to kill viruses like HIV.

Why aren't there more clinical trials for methylene blue in Alzheimer's or traumatic brain injury?

Despite methylene blue's potential and safety profile, there's little pharmaceutical interest because it's an old, unpatentable drug, meaning no company can profit significantly from its medical applications. This lack of economic incentive discourages large-scale clinical trials, leading to a state of limbo despite promising animal and preliminary human studies.

What is near-infrared light therapy and how does it affect mitochondrial function?

Near-infrared (NIR) light therapy involves transcranial delivery of specific wavelengths of light (e.g., 1064 nm) that are absorbed by cytochrome oxidase. This photo-oxidizes the enzyme, increasing its affinity for oxygen and promoting mitochondrial respiration. It's a localized, non-systemic approach targeting the prefrontal cortex to improve cognitive function.

How does the ketogenic diet promote brain health, particularly in older age?

The ketogenic diet facilitates mitochondrial respiration by providing ketone bodies as an alternative fuel source for the brain. While glucose uptake by the brain can be compromised with aging due to insulin resistance, the uptake of ketone bodies is not. This can help satisfy the brain's high energetic demands and is akin to the primary energy source in infancy.

How can regular fasting improve brain metabolic health?

Periodic fasting, such as for 14-16 hours, trains the body to upregulate ketogenesis enzymes. This allows the body to efficiently use its own stored fat to produce ketone bodies, providing a consistent energy supply to the brain and mitigating the effects of central and peripheral starvation often experienced at the cellular level despite caloric intake, especially in insulin-resistant individuals.

What are the most crucial risk factors for late-onset Alzheimer's besides age?

Beyond age, critical risk factors include atherosclerosis in major blood vessels (like carotid, aorta, renal arteries), hypertension, and underlying heart conditions that compromise the heart's pumping function. These factors contribute to chronic brain hypoperfusion, regardless of whether they lead to acute stroke-like events.

Key Moments

#38–Francisco Gonzalez-Lima, Ph.D.: Alzheimer’s disease & the vascular hypothesis

Peter Attia MD

People & Blogs3 min read153 min video

Jan 7, 2020|7,490 views|183|12

Save to Pod

Key Moments

On this page

TL;DR

Alzheimer's: It's a vascular energy crisis, not just amyloid. Methylene blue and NIR light show promise for treatment.

Key Insights

The dominant amyloid-beta hypothesis for Alzheimer's disease is likely false for late-onset dementia, potentially explaining research failures.

Late-onset Alzheimer's may stem from a progressive neuronal energy crisis due to impaired brain blood flow and mitochondrial respiration.

Methylene blue, at low concentrations, can act as an electron cycler in mitochondria, potentially aiding energy production and offering neuroprotection.

Near-infrared light therapy shows promise in stimulating mitochondrial function, particularly cytochrome oxidase, in the brain.

Cardiovascular health is crucial for brain health; interventions like blood pressure control and managing atherosclerosis can help prevent cognitive decline.

Ketogenic diets and exogenous ketone supplementation may benefit the brain by providing an alternative energy source that is not compromised by aging.

Rethinking Alzheimer's: Beyond the Amyloid Hypothesis

The prevailing amyloid-beta hypothesis for Alzheimer's disease, originating from early-onset cases, is questioned for its relevance to the more common late-onset dementia. Research failures suggest this focus may be misguided. Instead, a vascular hypothesis posits that the core issue is a progressive neuronal energy crisis, stemming from compromised blood flow and mitochondrial dysfunction.

The Neuronal Energy Crisis: Vascular Compromise and Mitochondrial Dysfunction

This alternative hypothesis suggests that reduced blood supply to the brain and impaired mitochondrial respiration create a chronic energy deficit. Age-related vascular changes, from macroscopic arterial stiffening to microscopic capillary issues, contribute to hypoperfusion. This energy deprivation affects the brain's high metabolic demands, leading to cognitive decline long before structural atrophy is evident.

Mitochondrial Respiration: The Crucial Role of Cytochrome Oxidase

Mitochondria are vital for energy production through oxidative phosphorylation, with cytochrome oxidase (complex IV) being the rate-limiting enzyme. Impaired circulation or direct insults can downregulate this enzyme, hindering oxygen utilization. This process is inducible, meaning it can be affected by both chronic hypoperfusion and other insults, making it a potential common denominator in various forms of dementia.

Therapeutic Avenues: Methylene Blue and Near-Infrared Light

Promising interventions target mitochondrial function. Methylene blue, at low, specific concentrations, can act as an electron cycler, supporting respiration and offering neuroprotection. Similarly, near-infrared light therapy can stimulate cytochrome oxidase, enhancing oxygen consumption. These approaches offer hope beyond traditional, often ineffective, Alzheimer's treatments.

The Importance of Cardiovascular Health for Brain Function

Maintaining good cardiovascular health is paramount for brain health. Conditions like hypertension and atherosclerosis compromise blood flow to the brain, exacerbating the energy crisis. Managing risk factors such as blood pressure, cholesterol, and inflammation can significantly contribute to preventing cognitive decline, highlighting the interconnectedness of heart and brain health.

Dietary Strategies: Ketogenic Diets and Brain Energy

Ketogenic diets offer an alternative energy source for the brain through ketone bodies, which may be more accessible than glucose, especially in aging brains with compromised glucose transport. This approach can facilitate mitochondrial respiration and potentially mitigate cognitive decline, offering a dietary strategy to support brain energy metabolism.

Repurposing Old Drugs and Novel Interventions

Methylene blue, a drug with a long history and well-understood safety profile, illustrates the potential of repurposing medications. Despite its benefits, lack of patentability hinders pharmaceutical development. Novel approaches like transcranial near-infrared light are also being explored, aiming to directly stimulate brain mitochondria and mitigate age-related cognitive decline.

The Challenge of Clinical Trials and Pharmaceutical Economics

The development of new treatments is hampered by pharmaceutical economics, as not all promising agents are patentable. Furthermore, current standards of care for Alzheimer's, like cholinesterase inhibitors, are largely ineffective and may even be detrimental. This creates a situation where potentially beneficial, low-cost interventions may not be rigorously tested or widely adopted.

Traumatic Brain Injury and Therapeutic Potential

The mechanisms discussed, particularly concerning mitochondrial dysfunction and energy deficits, may also be relevant to traumatic brain injury (TBI). Methylene blue could potentially serve as a rescue agent during or after TBI, mitigating transient insults. The potential for interventions to salvage neuronal function following acute injury warrants further investigation.

Mentioned in This Episode

●Organizations

●Books

●Drugs & Medications

●Concepts

●People Referenced

Common Questions

The main misunderstanding of Alzheimer's disease stems from its initial observation in a 51-year-old patient by Louis Alzheimer in 1907. This early-onset, often familial form, is distinct from the more common late-onset, age-related dementia that affects older people, yet most research has focused on the early-onset type, based on a false premise.

Topics

Health & Longevity Neuroscience & the Brain Mitochondrial Health Medicine & Clinical Alzheimer's Research Vascular Dementia Cognitive Impairment Methylene Blue Therapy Ketogenic Metabolism Transcranial Photobiomodulation

Mentioned in this video

People

Francisco Gonzalez-Lima

Professor of neuroscience and pharmacology and toxicology at the University of Texas Austin, and guest on this podcast episode.

Andriana Holly

Colleague of Dr. Gonzalez-Lima who received a grant from the National Institute on Aging to test transcranial near-infrared light in older individuals.

Jack de la Torre

Author of 'Alzheimer's Turning Point' and collaborator with Dr. Gonzalez-Lima on studies involving chronic hypoperfusion and cytochrome oxidase regulation in animal models.

Peter Attia

Host of The Drive podcast, interested in optimizing performance, health, and longevity.

Richard Isaacson

Colleague of Peter Attia who directs the Alzheimer's prevention clinic at Cornell.

Joan King

Professor at Tulane University who mentored Francisco Gonzalez-Lima during his honors thesis, focusing on brain, hormones, and behavior in animal models.

Paul Hanley Lu

A bioengineering professor in the Dallas area collaborating with Dr. Gonzalez-Lima on developing near-infrared spectroscopy devices to monitor changes in oxidized cytochrome oxidase in the human brain.

Oskar Fischer

Researcher who published studies on 16 brains from patients with senile dementia, describing similar abnormalities to those later published by Alzheimer but in older individuals.

Paul Ehrlich

A researcher known for his 'magic bullet' concept, who studied methylene blue's ability to stain nervous tissue and its potential as a medicinal application.

James Papez

An American neuroanatomist who described the 'Papez circuit,' a limbic circuit involved in emotional memory formation.

condition

Alzheimer's disease

A neurodegenerative disease that is the topic of this episode, with a focus on its vascular hypothesis.

Parkinson's disease

A neurodegenerative disorder primarily affecting the midbrain and brainstem, which can develop from head injuries and angular momentum.

Organizations

Tulane University

University in New Orleans where Francisco Gonzalez-Lima completed his undergraduate studies and developed an interest in the brain.

NIH Brain Initiative Program

A program by the National Institutes of Health that provided a grant for the development of near-infrared spectroscopy devices by Dr. Gonzalez-Lima's team.

National Institute on Aging

An NIH institute that provided a grant to Dr. Gonzalez-Lima and his colleague Andriana Holly to test transcranial near-infrared light in older people and those with mild cognitive impairment.

Concepts

PSEN2 gene

A gene mutation, along with PSEN1, associated with less than 1% of Alzheimer's disease cases, specifically early-onset forms.

PSEN1 gene

A gene mutation, along with PSEN2, associated with less than 1% of Alzheimer's disease cases, specifically early-onset forms.

Hippocampus

A region of the brain involved in memory formation and part of the limbic system, whose main input is from the entorhinal cortex.

Ketogenic Diet

A dietary approach that facilitates mitochondrial respiration by providing ketone bodies as an alternative energy source for the brain, whose uptake is not compromised during aging unlike glucose.

Plasmodium falciparum

The parasite that causes the most severe form of malaria, which Paul Ehrlich initially found methylene blue to be effective against.

Amyloid-beta hypothesis

The predominant but, according to the guest, false hypothesis stating that abnormal amyloid-beta protein depositions cause late-onset Alzheimer's disease.

Krebs Cycle

A central metabolic pathway in cells that produces energy, for which acetyl-CoA is an opening substrate.

Korsakoff dementia

A memory disorder, sometimes referred to as Korsakoff's psychosis, often developed by individuals with chronic alcohol abuse or thiamine deficiency, with damage primarily in the mammillary bodies.

Pyruvate dehydrogenase

An enzyme involved in energy metabolism that converts pyruvate to acetyl-CoA, which can be transiently inhibited by head trauma.

Drugs & Medications

Sodium Azide

A less potent inhibitor of the electron transport chain than cyanide, which can be used in animal models to induce cognitive impairment without immediate fatality, mimicking early dementia.

acetylcholinesterase inhibitors

A class of drugs commonly prescribed for Alzheimer's patients, but deemed ineffective and unethical to use due to lack of benefit and potential to accelerate decline according to the guest.

Chlorpromazine

The first psycho-pharmacological agent used for psychosis, developed in the late 1940s/early 1950s as a derivative of methylene blue.

Ifosfamide

A chemotherapy drug whose use can induce encephalopathy, a side effect that methylene blue has been found to prevent or rescue from.

Memantine

A drug approved for moderate to severe Alzheimer's, which prevents excitotoxicity but is considered counterproductive as it rescues functionally incompetent cells.

Supplements

Methylene blue

A synthetic dye discovered to act as an electron donor and cycler, facilitating mitochondrial respiration, and historically used for malaria and urinary infections. It also has neuroprotective qualities.

Cyanide

A classic poison that functions as a strong inhibitor of Cytochrome Oxidase (Complex IV), leading to rapid death at high concentrations but can induce Alzheimer's-like symptoms at very low doses.

Books

Alzheimer's Turning Point

A book written by Jack de la Torre, highly recommended as insight into Alzheimer's disease.